Astek Diagnostics, a Baltimore, MD-based developer of an urine-based diagnostic tool, received a Pre-Series A investment from She’s Independent.
Other investors included include Y Combinator, AYANA Capital, Wexford Scitech Venture Fund, Harvard Management Seed Capital, TEDCO, Maryland Momentum Fund, Goldin Ventures, Maryland Technology Development Corporation, Maryland Innovation Initiative, Maryland Industrial Partnerships, Key Technologies, Abell Foundation, and prominent angel investors. Astek has also received funding from the National Science Foundation, the Food and Drug Administration, the Biomedical Advanced Research and Development Authority, the National Institute of Health, and others.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Mustafa Al-Adhami, Astek is the developer of Jiddu™ Analyzer, an urine-based diagnostic tool. The company is actively working toward FDA marketing authorization application approval and has initiated collaborations with three independent urology clinics to demonstrate the feasibility of the Jiddu Analyzer in small clinical studies using real urine specimens. Astek recently initiated an early access program focused on urology clinics and hospitals in order to deploy the Jiddu Analyzer alpha prototype by mid-2024 in select locations.
FinSMEs
06/04/2024